外周T细胞淋巴瘤药物经济学评价的系统评价
Pharmacoeconomic evaluation for peripheral T-cell lymphoma:a systematic review
毛锌 1卢钰琼 1代展菁 1崔翔宇 1陈凯 1任挺 1路云 1常峰1
作者信息
- 1. 中国药科大学国际医药商学院,南京 211198
- 折叠
摘要
目的:系统评价外周T细胞淋巴瘤(peripheral T-cell lymphoma,PTCL)药物经济学研究,总结分析其方法学要点及经济性评价结果,为今后PTCL相关干预措施开展药物经济学评价提供参考.方法:计算机检索PubMed,Web of Science,The Cochrane Library,CNKI,WanFang Data和VIP等数据库中关于PTCL的药物经济学研究,检索时限均为建库至2023 年4 月,由2 名研究者独立筛选文献、提取关键信息并采用卫生经济学评价报告标准共识清单进行质量评价.结果:共纳入13 项研究,质量评价均分为84.07%,整体质量较好.12 项研究(92.3%)使用成本效用分析,11 项研究(84.6%)采用分区生存模型模拟至终生,且模型构建时考虑了干细胞移植情况,纳入研究的生存数据多采用标准参数模型(92.3%)或混合治愈模型(15.4%)进行拟合外推,成本以直接医疗成本为主,6 项研究(46.2%)额外考虑不良事件负效用.同时,12 项研究(92.3%)结果显示新药干预措施相比于常规疗法具有经济性优势.结论:纳入研究在干细胞移植设定、间接比较方法使用以及生存曲线拟合外推方法使用等方面存在一定差异.
Abstract
Objective:To systematically review the pharmacoeconomic evaluation of peripheral T-cell lymphoma(PTCL)and summarize and analyze model settings and other methodological points,thus to provide reference for pharmacoeconomic evaluation of PTCL-related interventions in the future.Methods:PubMed,Web of Science,The Cochrane Library,CNKI,WanFang Data,and VIP were electronically searched to collect relevant literature on the PTCL pharmacoeconomic evaluation from the inception of the database to April 2023.Two researchers independently screened literature,extracted key information from pharmacoeconomic evaluation,and appraised the quality of included studies by Consolidated Health Economic Evaluation Reporting Standards.Results:A total of 13 studies with an average score of 84.07%for quality assessment were included,indicating that the overall quality was good.Twelve studies(92.3%)used cost-utility analysis,11 studies(84.6%)mainly used partitioned survival model over a lifetime horizon,and included stem cell transplantation in their models.The survival data were mostly extrapolated by using standard parametric models(92.3%)or mixed cure models(15.4%).The cost was dominated by direct medical costs,and 6 studies(46.2%)additionally considered the negative effects of adverse events.The results of 12 studies(92.3%)showed that the new drug interventions in the research had economic advantages compared with standard therapy.Conclusion:There were some differences among the included studies in the settings of stem cell transplantation,the use of indirect comparison methods,and the use of survival curve fitting extrapolation methods.
关键词
外周T细胞淋巴瘤/药物经济学/系统评价Key words
peripheral T-cell lymphoma/pharmacoeconomics/systematic review引用本文复制引用
基金项目
2023年度江苏省卓越博士后计划(2023ZB105)
中国药科大学国际医药商学院横向课题项目(校合2022-商008)
出版年
2024
NETL
NSTL
万方数据